Cargando…

A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer

Companion diagnostic tests and targeted therapy changed the management of non-small cell lung cancer by diagnosing genetic modifications and enabling individualized treatment. The purpose of this systematic review is to assess the clinical applicability of companion diagnostic tests (IHC method) by...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Sulim, Woo, Jaehyun, Kim, Sungmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9140374/ https://www.ncbi.nlm.nih.gov/pubmed/35626451 http://dx.doi.org/10.3390/diagnostics12051297

Ejemplares similares

Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)
por: Takeuchi, K., et al.
Publicado: (2016)

Alectinib for treating patients with metastatic ALK-positive NSCLC: systematic review and network metanalysis
por: Samacá-Samacá, Daniel, et al.
Publicado: (2023)

ALK-Positive Squamous Cell Carcinoma Dramatically Responded to Alectinib
por: Sagawa, Ray, et al.
Publicado: (2018)

Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
por: Ulhoi, Maiken Parm, et al.
Publicado: (2021)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

Comparative Efficacy and Safety of Lorlatinib and Alectinib for ALK-Rearrangement Positive Advanced Non-Small Cell Lung Cancer in Asian and Non-Asian Patients: A Systematic Review and Network Meta-Analysis
por: Ando, Koichi, et al.
Publicado: (2021)

Case Report: Rare Systemic and Aggressive ALK-Positive Histiocytosis With Recurrent Pancreatitis Treating by Alectinib
por: Li, Yanchu, et al.
Publicado: (2022)

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
por: Watanabe, Satoshi, et al.
Publicado: (2022)

Chemotherapy versus alectinib for the treatment of crizotinib-pretreated ALK-positive patients with non small cell lung cancer: A protocol for systematic review and meta-analysis
por: Gao, Ting, et al.
Publicado: (2022)

STRN-ALK Fusion–Positive Case of Breast Cancer With Response to Alectinib
por: Kelly, Andrew D., et al.
Publicado: (2021)

Alectinib, an Anaplastic Lymphoma Kinase Inhibitor, Abolishes ALK Activity and Growth in ALK-Positive Neuroblastoma Cells
por: Alam, Muhammad Wasi, et al.
Publicado: (2019)

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
por: Morcos, Peter N., et al.
Publicado: (2018)

Bayesian analysis supports the role of alectinib and ensartinib for ALK‐positive non–small cell lung cancer
por: Rizzo, Alessandro
Publicado: (2023)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
por: Addeo, Alfredo, et al.
Publicado: (2018)

Successful Treatment with Ensartinib After Alectinib-induced Hyperbilirubinemia in ALK-Positive NSCLC
por: Peng, Ling, et al.
Publicado: (2021)

A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: A case report and review of the literature
por: De Smedt, Fabian, et al.
Publicado: (2022)

Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells
por: Furugaki, Koh, et al.
Publicado: (2021)

Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer
por: Shaw, Alice T., et al.
Publicado: (2015)

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
por: Karachaliou, Niki, et al.
Publicado: (2019)

Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
por: Mu, Lifeng, et al.
Publicado: (2020)

Progressive renal insufficiency related to ALK inhibitor, alectinib
por: Nagai, Kojiro, et al.
Publicado: (2018)

Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients
por: Martinez, Pablo, et al.
Publicado: (2013)

Successful salvage surgery followed by second ALK–TKI after alectinib failure in a patient with ALK-positive NSCLC
por: Hashimoto, Hiroshi, et al.
Publicado: (2022)

Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer
por: Okuma, Yusuke, et al.
Publicado: (2015)

Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
por: Yu, Hui, et al.
Publicado: (2019)

Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient: A case report
por: Thomas, Quentin Dominique, et al.
Publicado: (2021)

Major pathologic response to alectinib in ALK-rearranged adenocarcinoma of the lung
por: Imanishi, Naoko, et al.
Publicado: (2018)

STRN-ALK, A Novel In-Frame Fusion With Response to Alectinib
por: Nagasaka, Misako, et al.
Publicado: (2020)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

ALK Rearrangement in Small-Cell Lung Cancer and Durable Response to Alectinib: A Case Report
por: Sun, Ning, et al.
Publicado: (2021)

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK‐rearranged non‐small cell lung cancer
por: Ando, Chihiro, et al.
Publicado: (2023)

Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
por: Vavalà, Tiziana, et al.
Publicado: (2018)

Response Letter to “Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China”
por: Guan, Haijing, et al.
Publicado: (2020)

Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis
por: Tang, Hao, et al.
Publicado: (2021)

Primary resistance to alectinib in a patient with STRN‐ALK‐positive non‐small cell lung cancer: A case report
por: Sun, Kunyan, et al.
Publicado: (2021)

Clinical experience and management of adverse events in patients with advanced ALK-positive non-small-cell lung cancer receiving alectinib
por: Dziadziuszko, R., et al.
Publicado: (2022)

Real‐world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK‐positive non‐small‐cell lung cancer
por: Goto, Yasushi, et al.
Publicado: (2023)

The ALK inhibitors, alectinib and ceritinib, induce ALK‐independent and STAT3‐dependent glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2021)

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma
por: Adashek, Jacob J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h6jnis0tao4ka6rj7p08tgc6g2